期刊文献+

肝素类似物合成方法的研究进展 被引量:3

Research progress in the synthesis of heparin analogues
下载PDF
导出
摘要 肝素及低分子肝素是目前临床广泛应用的抗凝药物,其原料来源主要是猪小肠黏膜和牛肺黏膜,这不仅依赖屠宰业而且还被微生物污染,因此人工合成具有肝素类似结构及活性的物质是目前研究的热点。硫酸乙酰肝素是在肝素之后被发现的一类肝素类似物,在体内广泛存在。人工合成肝素类似物即是以天然肝素或硫酸乙酰肝素结构为模板,采用不同的方法合成。此文对国外报道的肝素类似物的几种合成方法进行综述。
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2010年第6期427-430,共4页 Chinese Journal of Biochemical Pharmaceutics
  • 相关文献

参考文献28

  • 1Smith S A,Dacvim M S.The cell-based model of coagulation[J].J Vet Emerg Crit Car,2009,19 (1):3-10.
  • 2Stringer S E.The role of heparan sulphate proteoglycans in angiogenesis[J].Biochem Soc Trans,2006,34:451-453.
  • 3李潇,孙永福,王凤山.低分子多糖在阿尔茨海默病防治中的研究进展[J].中国生化药物杂志,2009,30(5):344-347. 被引量:9
  • 4Parish C R.The role of heparan sulphate in inflammation[J].Nat Rev Immunol,2006,6:633-643.
  • 5Urbinati C,Nicoli S,Giacca M,et al.HIV-1 Tat and heparan sulfate proteoglycan interaction:a novel mechanism of lymphocyte adhesion and migration across the endothelium[J].Blood,2009,114(15):3335-3342.
  • 6Lambaerts K,Wilcox-Adelman S A,Zimmermann P.The signaling mechanisms of syndecan heparan sulfate proteoglycans[J].Curr Opin Cell Biol,2009,21 (5):662-669.
  • 7Singh O V,Harvey S P.Sustainable Biotechnology[M].Springer Netherlands,2010:259-277.
  • 8Bishop J R,Schuksz M,Esko J D.Heparan sulphate proteoglycans fine -tune mammalian physiology[J].Nature,2007,446:1030-1037.
  • 9Liu J,Pedersen L C.Anticoagulant heparan sulfate:structural specificity and biosynthesis[J].Appl Microbiol Biotechnol,2007,74:263-272.
  • 10Choay J,Petitou M,Lormeau J C,et al.Structure-activity relationship in heparin:a synthetic pentasaccharide with high affinity for antithrombin Ⅲ and eliciting high anti-factor Xa activity[J].Biochem Biophys Commun,1983,116 (2):492-499.

二级参考文献39

  • 1叶伟,唐孝威.老年性痴呆症发病机制及其防治措施的研究进展[J].国外医学(遗传学分册),2005,28(6):379-381. 被引量:11
  • 2邓少嫦,黄韧.硫酸乙酰肝素蛋白聚糖与阿尔茨海默病[J].中国神经精神疾病杂志,2006,32(1):91-92. 被引量:1
  • 3郭燕君,袁华,张俐娜,甘胜伟.灵芝多糖对阿尔茨海默病大鼠海马组织形态学及抗氧化能力的影响[J].解剖学报,2006,37(5):509-513. 被引量:15
  • 4Christopher B C, Gerard L C, Theresa A G. Development of photocrosslinked sialic acid containing polymers for use in Aβ toxicity attenuation [ J ]. Biomaterials, 2008,29 : 3408-3414.
  • 5Jack H, Johanneke K, Cathy N M, et al. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques[ J]. Neurobiol Aging, 2002, 23(4) :537-545.
  • 6John H, Dennis J S. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [ J ]. Science, 2002, 297(19) : 353-356.
  • 7Nienke M T, lack H, Irene O H, et al. Amyloid β induces cellular relocalization and production of agrin and glypican-1 [ J]. Brain Res, 2009, 1260:38-46.
  • 8Micha M M W, Robert M W W, Marcel M V. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer' s disease [ J ]. Mol Neurobiol, 2007,35 : 203-216.
  • 9Annika N A, Hinke A B M, John R C. Syndecans in wound healing, inflammation and vascular biology[ J]. Int J Biochem Cell Biol, 2007,39: 505-528.
  • 10Ilona B B, Tom G, Toin H K, Guido D, et al. Sulphate moieties of heparan sulphate proteoglyeans associaued with senile plaques in Alzheimer's disease[J]. Alzheimer Dement,2008,4(4):T714-T715.

共引文献8

同被引文献47

  • 1毛平,黄晓兰,李翠贞,陈蕃,关明媚,蔡小燕,黄润永,陈云华.高效液相色谱法测定血浆肝素含量[J].中华医学检验杂志,1995,18(6):358-360. 被引量:43
  • 2蔡炼,徐红.甲基紫共振瑞利散射法测微量肝素[J].化工时刊,2007,21(5):41-43. 被引量:3
  • 3Hirsh J,Warkentin T E,Shaughnessy S G. Heparin and lowmolecular-weight heparin:mechanisms of action,pharmacokinetics,dosing,monitoring,efficacy,and safety[J].Chest,2001,(1Suppl):64S-94S.
  • 4Bounameaux H. The novel anticoagulants:entering a new era[J].Swiss Medical Weekly,2009,(5-6):60-64.
  • 5Sundaram M,Qi Y W,Shriver Z. Rational design of low-molecular weight heparins with improved in vivo activity[J].Proceedings of the National Academy of Sciences(USA),2003,(02):651-656.
  • 6Shriver Z,Sundaram M,Venkataraman G. Low molecular weight heparin composition and uses thereof[P].US,0287683al,2007.
  • 7Kishimoto T K,Qi Y W,Long A. M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes[J].Thrombosis and Haemostasis,2009,(05):900-906.
  • 8Melloni C,Fier I,Roach J. Design and rationale of the evaluation of M118 IN percutaneous coronary intervention (EMI-NENCE) trial[J].American Heart Journal,2009,(05):726-733.
  • 9Francois P,Catherine. A Dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment:[P].WO/2010/106519,2010.
  • 10Viskov C,Just M,Laux V. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-lowmolecular-weight heparin,AVE5026[J].Journal of Thrombosis and Haemostasis,2009,(07):1143-1151.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部